New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
06:04 EDTRHHBYRoche says two phase III schizophrenia studies missed primary endpoints
Roche announced that two phase III studies of its investigational medicine bitopertin in adults with persistent, predominant negative symptoms of schizophrenia failed to meet their primary endpoints, based on the negative symptoms factor score of the positive and negative symptom scale. Negative symptoms include social withdrawal and lack of motivation. A third phase III study evaluating bitopertin for persistent, predominant negative symptoms of schizophrenia is ongoing. In addition, three phase III studies investigating bitopertin for sub-optimally controlled symptoms of schizophrenia are in progress. "These results are disappointing for people with negative symptoms because more effective treatments are needed for these debilitating effects of schizophrenia, said Sandra Horning, M.D., Chief Medical Officer at Roche. "We will await data from the remaining bitopertin studies in schizophrenia before deciding on next steps."
News For RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
07:51 EDTRHHBYRoche catching up fast to Bristol-Myers in immuno-oncology, says Jefferies
Subscribe for More Information
August 24, 2015
12:01 EDTRHHBYRoche buys nucleic acid purification technology from Lumora
Roche has signed a definitive asset purchase agreement with Lumora for products associated with the patent-protected Heat Elution technology for nucleic acid purification of multiple sample types including challenging formalin-fixed paraffin-embedded tumor samples. Roche plans to explore integrating this technology into its sequencing workflow solution.
August 23, 2015
12:35 EDTRHHBYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
09:38 EDTRHHBYUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
August 17, 2015
05:14 EDTRHHBYGenentech reports atezolizumab pivotal Phase II study met primary endpoint
Subscribe for More Information
August 13, 2015
06:16 EDTRHHBYRoche acquires GeneWEAVE to bolster offerings in microbiology diagnostics
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use